Natera Earnings Loom as Analysts Race to Raise Targets

NTRA reports Q3 results on November 5, with the stock at $414.30 after a 5% drop on October 30 wiped out most of a modest weekly gain, leaving shares roughly flat over the past month while the broader biotech peer group ran considerably hotter.

The most striking pre-earnings development is the scale and unanimity of analyst target revisions. Every firm that moved in October went higher, and the moves were large. JP Morgan lifted its target to $460 from $360 on October 14, Morgan Stanley moved to $435 from $355 on October 13, and TD Cowen went all the way to $480 from $340 the same day. Canaccord Genuity pushed to $500 on October 19, followed by BTIG raising to $430 from $320 on October 27. The consensus sits at Buy across all 17 covering analysts, with a mean target of $411. That places the current share price effectively at consensus, which is an unusual position: the stock has appreciated so quickly that the Street's upgrades are now playing catch-up rather than pointing meaningfully higher. ORTEX puts the chance of NTRA joining the Nasdaq-100 at 69% in the December 2026 Annual Review, with a projected $5.2 billion of index-tracker buying required if the addition goes through, equivalent to 7.9 days of normal trading volume.

The bull case rests on Signatera's dominance in the MRD market, where Natera claims over 90% share, with volume growing around 60% in 2025. The current Signatera average selling price of $1,275 sits well below the $3,590 Medicare reimbursement rate, and the company's cost per test has fallen more than $100 since 2022, creating a credible path toward 70%-plus gross margins over time. Bears counter that penetration in established indications like colorectal cancer adjuvant treatment already exceeds 50%, narrowing the incremental growth runway. They also point to a more crowded MRD competitive field and note that ASP expansion from roughly $500 to $1,250 over five years has not been smooth, making the path to the $2,000 target uncertain.

Positioning does not suggest aggressive short pressure. Short interest has dropped 10% over the past week to 4.2% of the free float, and the borrow market is extraordinarily loose, with availability at 9,211%, meaning shares to lend are plentiful relative to existing shorts. The cost to borrow is negligible at 0.42%, down sharply from over 1% earlier in the period. Options tell a different story from early October: the put/call ratio has fallen to 0.80, more than 1.3 standard deviations below its 20-day average of 0.93, reflecting a shift toward call activity rather than defensive hedging. Wikipedia attention for the company scored a z-score of 2.5 above its own 90-day baseline in late October, pointing to an uptick in retail interest ahead of the print.

All insider activity in the past 90 days has been selling: a net $31 million in shares disposed of, including CEO Steven Chapman selling $1.46 million on October 28. Every reported transaction was executed under a pre-arranged 10b5-1 plan, which limits the signal value considerably, but the consistency across the C-suite is notable. The November 5 print is therefore less a test of whether Natera is growing and more a question of whether Signatera's volume trajectory and improving unit economics can sustain a valuation that has moved so fast the analyst community is still adjusting its models to catch up.